OcuLearning › Retina

Best Disease (Vitelliform Macular Dystrophy)

CHRONIC — Retina

Symptoms

Presentation

  • Decreased central visual acuity.
  • Metamorphopsia or central scotoma.
  • Frequently asymptomatic; often identified during routine exams or family screening.

Clinical Findings

Hallmark morphology

  • Round, yellow-orange "egg-yolk" (vitelliform) subretinal foveal deposit.
  • Typically 1–2 disc diameters in size and bilateral.
  • Material consists of lipofuscin situated between the photoreceptor outer segments and the retinal pigment epithelium (RPE).

Five clinical stages

  • Stage 1 (previtelliform): Normal fundus but abnormal EOG (identifies carriers).
  • Stage 2 (vitelliform): Classic "egg-yolk intact" lesion; vision often remains 20/20–20/40.
  • Stage 3 (pseudohypopyon): Yellow material layers inferiorly within subretinal fluid.
  • Stage 4 (vitelliruptive): "Scrambled egg" appearance as material breaks up; vision begins to decline.
  • Stage 5 (atrophic/cicatricial): Macular atrophy or fibrosis; mimics dry AMD. Choroidal neovascularization (CNV) develops in ~20%.

Electrophysiologic signature

  • EOG: Markedly abnormal with an Arden ratio <1.5 (hallmark sign).
  • ERG: Normal full-field response (photoreceptor function is preserved).
  • Diagnostic triad: Abnormal EOG + normal ERG + vitelliform lesion.

Imaging characteristics

  • OCT: Hyperreflective subretinal material between the neurosensory retina and RPE.
  • FAF: Intense hyperautofluorescence of the "yolk" (fresh lipofuscin); fades with atrophy.

Genetics and associations

  • Autosomal dominant with variable penetrance (BEST1/VMD2 mutation).
  • Associated with short axial length (hyperopia) and increased risk of angle-closure glaucoma.

Differential: adult-onset foveomacular vitelliform (AOFVD)

  • Presents later (4th–6th decade) with smaller lesions (1/3 disc diameter).
  • Characterized by a normal EOG and often PRPH2 mutations.

Etiology

Genetic basis

  • Bestrophin-1 mutation (BEST1/VMD2 gene).
  • Affects a calcium-activated chloride channel on the basolateral RPE membrane.

Pathomechanism

  • RPE dysfunction leads to lipofuscin accumulation between the RPE and photoreceptors.
  • Progressive stages lead from lipofuscin "yolk" deposits to eventual macular atrophy or scarring.

Red Flags

  • Sudden vision drop or metamorphopsia in stages 2–5: Indicates secondary CNV.
  • Abnormal EOG Arden ratio (<1.5) with normal ERG: Confirms diagnosis.
  • Family history of macular disease: Warrants cascade screening of relatives.
  • Shallow anterior chambers: High risk for angle-closure glaucoma.

Investigations

Functional testing

  • EOG: Essential to confirm Arden ratio <1.5.
  • ERG: Full-field testing to confirm normal photoreceptor function.

Structural imaging

  • OCT: To monitor for subretinal fluid or CNV development.
  • FAF: To evaluate lipofuscin distribution and lesion activity.

Genetic confirmation

  • BEST1 gene mutation analysis.

Treatment

Management strategy

  • Observation: Standard for early stages with stable vision.
  • Vision rehabilitation: Low-vision aids for advanced atrophic disease.

Complication care

  • Intravitreal anti-VEGF (aflibercept, ranibizumab, or bevacizumab): First-line for secondary CNV.
  • No current medical or surgical therapy alters the natural history of the dystrophy.

Clinical Pearl

The definitive signature of Best disease is a markedly reduced Arden ratio on EOG (<1.5) despite a normal full-field ERG, paired with the classic "egg-yolk" foveal lesion.

Differential Diagnosis

  • Adult-onset foveomacular vitelliform dystrophy (AOFVD)
  • Pattern dystrophy
  • Age-related macular degeneration (AMD)
  • Central serous chorioretinopathy

Related Retina Conditions